For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 |
|---|---|---|---|---|
| Total operating expenses | - | - | - | 42,256 |
| Total revenues | 1,083 | 1,463* | 1,666 | 52 |
| Cost of sales | 2,962 | -84* | 1,577 | - |
| Research and development | 43,730 | 35,980* | 27,884 | 27,467 |
| General and administrative | 20,780 | 16,342* | 23,334 | 14,789 |
| Total operating costs and expenses | 67,472 | 52,237* | 52,795 | - |
| Loss from operations | -66,389 | -50,774* | -51,129 | -42,204 |
| Interest income, net | 6,288 | 7,180* | 7,421 | 7,747 |
| Other (expense) income, net | -101 | -9* | -100 | 5 |
| Total other income, net | 6,187 | 7,170* | 7,321 | 7,752 |
| Net loss and comprehensive loss | -60,202 | -43,605 | -43,808 | -34,452 |
| Net loss attributable to common stockholders | - | -43,605 | - | - |
| Basic EPS | -0.71 | -0.552 | -0.57 | -0.45 |
| Diluted EPS | -0.71 | -0.552 | -0.57 | -0.45 |
| Basic Average Shares | 84,518,512 | 78,992,973 | 76,729,726 | 76,187,621 |
| Diluted Average Shares | 84,518,512 | 78,992,973 | 76,729,726 | 76,187,621 |
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)